Decidual stromal cells for the treatment of severe COVID-19 ARDS

Intensive Care Med. 2023 Dec;49(12):1552-1554. doi: 10.1007/s00134-023-07262-x. Epub 2023 Nov 15.

Authors

John Granton^#^{1

2}, Igor N Novitzky-Basso^#^{3

4}, Alexandra Binnie⁵, Jonas Mattsson^{3

4

6}; DSC Study Group

Collaborators

DSC Study Group:
Michael Beyea, Mats Remberger, Clair Moura, Judy Lew, Cindy Yau, Anuj Singla, Hanne Scholz, Yngvar Fløisand, Lorenzo Del Sorbo, Sanjay Mehta, Arthur Slutsky, John Laffey

Affiliations

¹ Department of Medicine, University Health Network, Faculty of Medicine, University of Toronto, Toronto, Canada. john.granton@uhn.ca.
² Toronto General Hospital, Toronto, Canada. john.granton@uhn.ca.
³ Department of Medicine, University Health Network, Faculty of Medicine, University of Toronto, Toronto, Canada.
⁴ Hans Messner Blood and Marrow Allogeneic Stem Cell Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
⁵ William Osler Health System, Toronto, Canada.
⁶ Gloria and Seymour Epstein Chair in Cellular, Therapy University of Toronto, Toronto, Canada.

^# Contributed equally.

PMID: 37968285
DOI: 10.1007/s00134-023-07262-x

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Humans
Respiratory Distress Syndrome* / therapy
Stromal Cells

Grants and funding

(VR 2017-00355)/Swedish Research Council